BIIB
- Biogen Inc.
()
Overview
Company Summary
Biogen Inc. is a leading biotechnology company focused on the development and commercialization of innovative therapies for various neurological, autoimmune, and rare diseases. Based in Cambridge, Massachusetts, Biogen's mission is to transform the lives of patients by discovering, developing, and delivering breakthrough treatments.
Biogen specializes in neuroscience, with a particular emphasis on neurodegenerative diseases such as multiple sclerosis (MS), spinal muscular atrophy (SMA), and amyotrophic lateral sclerosis (ALS). The company's expertise extends beyond traditional small molecule drugs, as it has pioneered the use of biotechnology and advanced therapies, including recombinant DNA technology and biologics.
Biogen manufactures and markets some of the most well-known and widely prescribed treatments in the field of neurology. One of its most successful drugs is TECFIDERA� (dimethyl fumarate), which is used to treat relapsing forms of MS. Biogen also develops and markets additional MS therapies, such as AVONEX� (interferon beta-1a), PLEGRIDY� (peginterferon beta-1a), and TYSABRI� (natalizumab).
In recent years, Biogen expanded its focus beyond neurology to include immunology and rare diseases. It has developed innovative treatments like SPINRAZA� (nusinersen), the first approved therapy for SMA and a groundbreaking medication for patients, including children, who suffer from spinal muscular atrophy.
Additionally, Biogen is committed to advancing scientific research and innovation in collaboration with various academic institutions, healthcare organizations, and other biotechnology companies. The company is constantly exploring new avenues and investing in research with the aim of bringing meaningful therapies to patients who are otherwise underserved or facing limited treatment options.
Overall, Biogen's dedication to scientific excellence, commitment to in-depth research, and patient-centric approach have solidified its position as a frontrunner in the field of biotechnology, particularly in the treatment of neurological and rare diseases.